Tingting Li1, Yingyi Zhang2, Hongliang Cong3. 1. Tianjin Medical University, Department of Cardiology, Tianjin Chest Hospital, Tianjin, China. 2. Department of Cardiology, Tianjin Chest Hospital, No. 261 Taierzhuang South Road, Jinnan District, Tianjin, China. 3. Department of Cardiology, Tianjin Chest Hospital, No. 261 Taierzhuang South Road, Jinnan District, Tianjin, China. hongliangcong2871@163.com.
Abstract
BACKGROUND: To assess the effects of proprotein convertase subtilisin/kexin type 9 inhibitor (evolocumab) on lipoprotein particles subfractions with Nuclear Magnetic Resonance spectroscopy in patients with acute coronary syndromes. METHODS: A total of 99 consecutive patients with ACS were enrolled and assigned to either the experimental group (n = 54) or the control group (n = 45). The combination therapy of PCSK9 inhibitor (Repatha®, 140 mg, q2w) and moderate statin (Rosuvastatin, 10 mg, qn) was administered in the experimental group, with statin monotherapy (Rosuvastatin, 10 mg, qn) in the control group. The therapeutic effects on lipoprotein particle subfractions were assessed with NMR spectroscopy after 8 weeks treatment, and the achievement of LDL-C therapeutic target in both groups were analyzed. RESULTS: In the experimental group, after 8 weeks of evolocumab combination treatment, the concentrations of blood lipids (TC, LDL-C and its subfractions [LDL-1 to 6], VLDL-C and its subfractions [VLDL-1 to 5], IDL-C, and HDL-C), lipoprotein particles, and their subfractions [VLDL-P, IDL-P, LDL-P, and its subfractions [LDL-P1 to 6], apoB, and LP(a)] demonstrated therapeutic benefits with statistical significance (P < 0.05). The decrease in total LDL-P concentrations was mainly due to a decreased concentration of small-sized LDL particles (LDL-P 5 + 6), which was significantly more prominent than the decrease in medium-sized LDL-P (LDL-P3 + 4) and large-sized LDL-P (LDL-P1 + 2) (P < 0.001). According to lipid control target recommended by the latest China Cholesterol Education Program Expert Consensus in 2019, after 8 weeks treatment, 96.3% patients in the experimental group and 13.3% in the control group had achieved the LDL-C therapeutic target (P < 0.01). CONCLUSIONS: Evolocumab combination treatment for 8 weeks significantly improves the plasma lipid profiles in ACS patients, and significantly decrease the concentration of lipoprotein particles which might contribute to the pathonesis of atherosclerosis.
RCT Entities:
BACKGROUND: To assess the effects of proprotein convertase subtilisin/kexin type 9 inhibitor (evolocumab) on lipoprotein particles subfractions with Nuclear Magnetic Resonance spectroscopy in patients with acute coronary syndromes. METHODS: A total of 99 consecutive patients with ACS were enrolled and assigned to either the experimental group (n = 54) or the control group (n = 45). The combination therapy of PCSK9 inhibitor (Repatha®, 140 mg, q2w) and moderate statin (Rosuvastatin, 10 mg, qn) was administered in the experimental group, with statin monotherapy (Rosuvastatin, 10 mg, qn) in the control group. The therapeutic effects on lipoprotein particle subfractions were assessed with NMR spectroscopy after 8 weeks treatment, and the achievement of LDL-C therapeutic target in both groups were analyzed. RESULTS: In the experimental group, after 8 weeks of evolocumab combination treatment, the concentrations of blood lipids (TC, LDL-C and its subfractions [LDL-1 to 6], VLDL-C and its subfractions [VLDL-1 to 5], IDL-C, and HDL-C), lipoprotein particles, and their subfractions [VLDL-P, IDL-P, LDL-P, and its subfractions [LDL-P1 to 6], apoB, and LP(a)] demonstrated therapeutic benefits with statistical significance (P < 0.05). The decrease in total LDL-P concentrations was mainly due to a decreased concentration of small-sized LDL particles (LDL-P 5 + 6), which was significantly more prominent than the decrease in medium-sized LDL-P (LDL-P3 + 4) and large-sized LDL-P (LDL-P1 + 2) (P < 0.001). According to lipid control target recommended by the latest China Cholesterol Education Program Expert Consensus in 2019, after 8 weeks treatment, 96.3% patients in the experimental group and 13.3% in the control group had achieved the LDL-C therapeutic target (P < 0.01). CONCLUSIONS:Evolocumab combination treatment for 8 weeks significantly improves the plasma lipid profiles in ACS patients, and significantly decrease the concentration of lipoprotein particles which might contribute to the pathonesis of atherosclerosis.
Authors: Zeljko Reiner; Alberico L Catapano; Guy De Backer; Ian Graham; Marja-Riitta Taskinen; Olov Wiklund; Stefan Agewall; Eduardo Alegria; M John Chapman; Paul Durrington; Serap Erdine; Julian Halcox; Richard Hobbs; John Kjekshus; Pasquale Perrone Filardi; Gabriele Riccardi; Robert F Storey; David Wood Journal: Eur Heart J Date: 2011-06-28 Impact factor: 29.983
Authors: B Lamarche; A Tchernof; S Moorjani; B Cantin; G R Dagenais; P J Lupien; J P Després Journal: Circulation Date: 1997-01-07 Impact factor: 29.690
Authors: James D Otvos; Samia Mora; Irina Shalaurova; Philip Greenland; Rachel H Mackey; David C Goff Journal: J Clin Lipidol Date: 2011 Mar-Apr Impact factor: 4.766
Authors: Keith A A Fox; Frederick A Anderson; Shaun G Goodman; P Gabriel Steg; Karen Pieper; Ann Quill; Joel M Gore Journal: Nat Clin Pract Cardiovasc Med Date: 2008-07-29
Authors: Anthony C Dona; Beatriz Jiménez; Hartmut Schäfer; Eberhard Humpfer; Manfred Spraul; Matthew R Lewis; Jake T M Pearce; Elaine Holmes; John C Lindon; Jeremy K Nicholson Journal: Anal Chem Date: 2014-09-16 Impact factor: 6.986
Authors: Lars Harbaum; Pavandeep Ghataorhe; Christopher J Rhodes; Martin R Wilkins; John Wharton; Beatriz Jiménez; Luke S G Howard; J Simon R Gibbs; Jeremy K Nicholson Journal: Thorax Date: 2018-11-26 Impact factor: 9.102
Authors: Michael J Koren; Dean Kereiakes; Ray Pourfarzib; Deborah Winegar; Poulabi Banerjee; Sara Hamon; Corinne Hanotin; James M McKenney Journal: J Am Heart Assoc Date: 2015-11-19 Impact factor: 5.501
Authors: Ana Milojević; Marija Zdravković; Milica Brajković; Lidija Memon; Vera Gardijan; Jelena Vekić; Aleksandra Zeljković; Aleksandra Stefanović; Marija Mihajlović; Jasmina Ivanišević; Nataša Bogavac-Stanojević; Vojislav Radosavljević; Vesna Spasojević-Kalimanovska; Ana Ninić Journal: Med Princ Pract Date: 2022-03-15 Impact factor: 2.132
Authors: Elisa Waldmann; Liya Wu; Kristina Busygina; Julia Altenhofer; Kerstin Henze; Alexander Folwaczny; Klaus G Parhofer Journal: PLoS One Date: 2022-03-23 Impact factor: 3.240